Skip to content

Study · Non-randomized trial · n = 7 · 1985

15 results

Dose-related changes in LH bioactivity with intranasal GnRH agonist administration.

Chiang RS, Barnes RB, Shoupe D, Lobo RA

Contraception1 Oct 1985Cited by 7 (Europe PMC)

PMID2934222 (opens in a new tab)DOI10.1016/0010-7824(85)90038-1 (opens in a new tab)PepBankPUB-02934222
Publisher pagePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    In normal women, maximum gonadotropin changes occurred 2-4 hours after first and last nafarelin doses.

    In plain wordsIn normal women, maximum gonadotropin changes occurred 2-4 hours after first and last nafarelin doses.

    Peptide
    Nafarelin
    Outcome
    Not applicableTime to maximum gonadotropin changes
    Study

    n = 7

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    125 or 250 micrograms · intranasal · 14 weeksAs given in this study (human).

    Measurements

    Time to maximum gonadotropin change
    2 to 4 hours
    after first and last doses

    Source sentences

    Summary
    Maximum changes in gonadotropins were observed 2-4 hours after both the first and last doses.
    1 context sentence
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  2. 02HumanNon-randomized trialActivity measurement

    In normal women, nafarelin reduced maximum acute immunoreactive LH responses after 14 weeks.

    In plain wordsIn normal women, maximum acute immunoreactive LH responses fell after 14 weeks of nafarelin.

    Peptide
    Nafarelin
    Outcome
    DecreaseAcute immunoreactive LH response
    Study

    n = 7

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    125 or 250 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    However, the maximum acute responses of iLH, bioLH and FSH were significantly reduced after 14 weeks of treatment while no changes occurred in the bio: iLH ratio.
    2 context sentences
    Summary · context
    The decrease in these acute responses were not dose-related.
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  3. 03HumanNon-randomized trialActivity measurement

    In normal women, nafarelin reduced maximum acute bioactive LH responses after 14 weeks.

    In plain wordsIn normal women, maximum acute bioactive LH responses fell after 14 weeks of nafarelin.

    Peptide
    Nafarelin
    Outcome
    DecreaseAcute bioactive LH response
    Study

    n = 7

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    125 or 250 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    However, the maximum acute responses of iLH, bioLH and FSH were significantly reduced after 14 weeks of treatment while no changes occurred in the bio: iLH ratio.
    2 context sentences
    Summary · context
    The decrease in these acute responses were not dose-related.
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  4. 04HumanNon-randomized trialActivity measurement

    In normal women, nafarelin reduced maximum acute FSH responses after 14 weeks.

    In plain wordsIn normal women, maximum acute FSH responses fell after 14 weeks of nafarelin.

    Peptide
    Nafarelin
    Outcome
    DecreaseAcute FSH response
    Study

    n = 7

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    125 or 250 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    However, the maximum acute responses of iLH, bioLH and FSH were significantly reduced after 14 weeks of treatment while no changes occurred in the bio: iLH ratio.
    2 context sentences
    Summary · context
    The decrease in these acute responses were not dose-related.
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  5. 05HumanNon-randomized trialActivity measurement

    In normal women, the acute bioactive to immunoreactive LH ratio did not change after nafarelin treatment.

    In plain wordsIn normal women, the acute bioactive to immunoreactive LH ratio did not change after nafarelin treatment.

    Peptide
    Nafarelin
    Outcome
    No significant changeAcute bioactive to immunoreactive LH ratio
    Study

    n = 7

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    125 or 250 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    However, the maximum acute responses of iLH, bioLH and FSH were significantly reduced after 14 weeks of treatment while no changes occurred in the bio: iLH ratio.
    1 context sentence
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  6. 06HumanNon-randomized trialActivity measurement

    In normal women, reductions in acute gonadotropin responses after 14 weeks of nafarelin were not dose-related.

    In plain wordsIn normal women, acute hormone response reductions after nafarelin did not depend on dose.

    Peptide
    Nafarelin
    Outcome
    No significant changeDose dependence of acute gonadotropin response reduction
    Study

    n = 7

    Comparator
    125 versus 250 micrograms nafarelin
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    125 or 250 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    The decrease in these acute responses were not dose-related.
    2 context sentences
    Summary · context
    However, the maximum acute responses of iLH, bioLH and FSH were significantly reduced after 14 weeks of treatment while no changes occurred in the bio: iLH ratio.
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  7. 07HumanNon-randomized trialActivity measurement

    In normal women, baseline immunoreactive LH did not change significantly with nafarelin at 125 micrograms.

    In plain wordsIn normal women, baseline immunoreactive LH did not change significantly with nafarelin at 125 micrograms.

    Peptide
    Nafarelin
    Outcome
    No significant changeBaseline immunoreactive LH
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    125 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum iLH and FSH levels obtained prior to each dose (baseline) were not significantly altered by 14 weeks with either dose.
    1 context sentence
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  8. 08HumanNon-randomized trialActivity measurement

    In normal women, baseline immunoreactive LH did not change significantly with nafarelin at 250 micrograms.

    In plain wordsIn normal women, baseline immunoreactive LH did not change significantly with nafarelin at 250 micrograms.

    Peptide
    Nafarelin
    Outcome
    No significant changeBaseline immunoreactive LH
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    250 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum iLH and FSH levels obtained prior to each dose (baseline) were not significantly altered by 14 weeks with either dose.
    1 context sentence
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  9. 09HumanNon-randomized trialActivity measurement

    In normal women, baseline FSH did not change significantly with nafarelin at 125 micrograms.

    In plain wordsIn normal women, baseline FSH did not change significantly with nafarelin at 125 micrograms.

    Peptide
    Nafarelin
    Outcome
    No significant changeBaseline FSH
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    125 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum iLH and FSH levels obtained prior to each dose (baseline) were not significantly altered by 14 weeks with either dose.
    1 context sentence
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  10. 10HumanNon-randomized trialActivity measurement

    In normal women, baseline FSH did not change significantly with nafarelin at 250 micrograms.

    In plain wordsIn normal women, baseline FSH did not change significantly with nafarelin at 250 micrograms.

    Peptide
    Nafarelin
    Outcome
    No significant changeBaseline FSH
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    250 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Serum iLH and FSH levels obtained prior to each dose (baseline) were not significantly altered by 14 weeks with either dose.
    1 context sentence
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  11. 11HumanNon-randomized trialActivity measurement

    In normal women, nafarelin at 250 micrograms significantly reduced baseline bioactive LH versus pretreatment.

    In plain wordsIn normal women, nafarelin at 250 micrograms reduced baseline bioactive LH versus pretreatment.

    Peptide
    Nafarelin
    Outcome
    DecreaseBaseline bioactive LH
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    250 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    However, baseline serum bioLH was significantly reduced compared to pretreatment by 14 weeks but only with the 250 micrograms dose (p less than 0.05).
    1 context sentence
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  12. 12HumanNon-randomized trialActivity measurement

    In normal women, nafarelin at 125 micrograms did not significantly reduce baseline bioactive LH versus pretreatment.

    In plain wordsIn normal women, nafarelin at 125 micrograms did not significantly reduce baseline bioactive LH versus pretreatment.

    Peptide
    Nafarelin
    Outcome
    No significant changeBaseline bioactive LH
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    125 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    However, baseline serum bioLH was significantly reduced compared to pretreatment by 14 weeks but only with the 250 micrograms dose (p less than 0.05).
    1 context sentence
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  13. 13HumanNon-randomized trialActivity measurement

    In normal women, baseline bioactive LH with nafarelin at 250 micrograms differed significantly from the level with 125 micrograms (p less than 0.05).

    In plain wordsIn normal women, baseline bioactive LH with nafarelin at 250 micrograms differed from the level with 125 micrograms.

    Peptide
    Nafarelin
    Outcome
    Direction not reportedBaseline bioactive LH dose comparison
    Study

    n: not reported in source

    Comparator
    125 micrograms nafarelin
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    250 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    This level was also significantly different from the level of bioLH achieved with 125 micrograms (p less than 0.05).
    2 context sentences
    Summary · context
    However, baseline serum bioLH was significantly reduced compared to pretreatment by 14 weeks but only with the 250 micrograms dose (p less than 0.05).
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  14. 14HumanNon-randomized trialActivity measurement

    In normal women, nafarelin at 250 micrograms significantly decreased the bioactive to immunoreactive LH ratio.

    In plain wordsIn normal women, nafarelin at 250 micrograms decreased the bioactive to immunoreactive LH ratio.

    Peptide
    Nafarelin
    Outcome
    DecreaseBaseline bioactive to immunoreactive LH ratio
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    250 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    The bio: iLH ratio was also significantly decreased with the 250 micrograms dose.
    1 context sentence
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.
  15. 15HumanNon-randomized trialActivity measurement

    In normal women, hormones suggested follicular activity and luteinization with nafarelin at 125 micrograms but not 250 micrograms.

    In plain wordsIn normal women, hormones suggested ovarian activity with nafarelin at 125 micrograms but not 250 micrograms.

    Peptide
    Nafarelin
    Outcome
    DecreaseOvarian follicular activity and luteinization
    Study

    n: not reported in source

    Comparator
    125 micrograms nafarelin
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    250 micrograms · intranasal · 14 weeksAs given in this study (human).

    Source sentences

    Summary
    Although serum estradiol and progesterone levels suggested ovarian follicular activity and luteinization with the 125 micrograms dose, this did not occur with 250 micrograms of intranasal nafarelin.
    1 context sentence
    Summary · context
    In order to evaluate changes in bioactive (bio) and immunoreactive (i) LH and in FSH after intranasal administration of a GnRH agonist, two doses (125 micrograms and 250 micrograms) of nafarelin acetate were administered for 14 weeks to 7 normal women.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.